Swiss National Bank
PHAT icon

Swiss National Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Swiss National Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03M Buy
92,600
+8,600
+10% +$109K ﹤0.01% 2147
2025
Q4 		$1.39M Buy
+84,000
New +$1.2M ﹤0.01% 2028
2025
Q2 		– Sell
-73,300
Closed -$460K – 2387
2025
Q1 		$460K Hold
73,300
– – ﹤0.01% 2354
2024
Q4 		$595K Hold
73,300
– – ﹤0.01% 2371
2024
Q3 		$1.33M Buy
73,300
+17,300
+31% +$242K ﹤0.01% 2087
2024
Q2 		$577K Hold
56,000
– – ﹤0.01% 2385
2024
Q1 		$595K Hold
56,000
– – ﹤0.01% 2415
2023
Q4 		$511K Sell
56,000
-4,200
-7% -$36.2K ﹤0.01% 2470
2023
Q3 		$624K Sell
60,200
-11,300
-16% -$155K ﹤0.01% 2453
2023
Q2 		$1.02M Buy
71,500
+31,100
+77% +$359K ﹤0.01% 2280
2023
Q1 		$288K Sell
40,400
-1,100
-3% -$9.66K ﹤0.01% 2612
2022
Q4 		$466K Hold
41,500
– – ﹤0.01% 2586
2022
Q3 		$460K Hold
41,500
– – ﹤0.01% 2598
2022
Q2 		$350K Buy
41,500
+8,100
+24% +$83.3K ﹤0.01% 2689
2022
Q1 		$455K Buy
33,400
+2,400
+8% +$38.8K ﹤0.01% 2615
2021
Q4 		$610K Hold
31,000
– – ﹤0.01% 2627
2021
Q3 		$995K Hold
31,000
– – ﹤0.01% 2441
2021
Q2 		$1.05M Buy
31,000
+14,400
+87% +$516K ﹤0.01% 2463
2021
Q1 		$623K Buy
16,600
+500
+3% +$20.9K ﹤0.01% 2438
2020
Q4 		$535K Hold
16,100
– – ﹤0.01% 2451
2020
Q3 		$590K Hold
16,100
– – ﹤0.01% 2325
2020
Q2 		$530K Buy
+16,100
New +$619K ﹤0.01% 2370

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Swiss National Bank's PHAT Position: Q1 2026 in Review

Swiss National Bank increased its Phathom Pharmaceuticals (PHAT) stake by 10% in Q1 2026, buying an estimated $109K and bringing the position to 92,600 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2147.

Swiss National Bank first reported a position in PHAT in Q2 2020 and has held it in 22 quarters since. The position peaked at $1.39M in Q4 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Swiss National Bank held 92,600 shares of Phathom Pharmaceuticals worth $1.03M as of Q1 2026.
  • Swiss National Bank bought 8,600 Phathom Pharmaceuticals shares in Q1 2026, an estimated $109K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2147 holding.
  • Swiss National Bank first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Swiss National Bank's Phathom Pharmaceuticals position peaked at $1.39M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.